Clinical Trial Update: T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating T-cells expressing an anti-SLAMF7 CAR for treating multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• anti-SLAMF7 CAR-T cells (SLAMF7-targeted CAR-T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Status: COMPLETED | Results posted: 2021-09-09